← All companies

GENB

Generate Biomedicines, Inc.

GENB Nasdaq Pharmaceutical Preparations EDGAR ↗

$14.34

+0.34 +2.43%

Key statistics

from XBRL data in SEC filings

Market cap

$1.84B

Revenue (TTM)

—

Net income (TTM)

—

EPS (TTM)

—

P/E ratio

—

Dividend yield

—

Free cash flow

—

Cash

$161M

Total assets

$626M

Gross margin

—

52-week range

$11.00 – $18.18

Recent SEC filings

40 most recent

Annual, quarterly & current reports

10-Q Quarter ended 2026-03-31 May 7, 2026 8-K Results of operations (earnings release) May 7, 2026 8-K Amended charter or bylaws Mar 2, 2026

Other filings

SCHEDULE 13G May 15, 2026 SCHEDULE 13G May 15, 2026 3 Mar 12, 2026 4 Mar 6, 2026 4 Mar 2, 2026 4 Mar 2, 2026 4 Mar 2, 2026 4 Mar 2, 2026 4 Mar 2, 2026 4 Mar 2, 2026 4 Mar 2, 2026 4 Mar 2, 2026 4 Mar 2, 2026 4 Mar 2, 2026 4 Mar 2, 2026 4 Mar 2, 2026 4 Mar 2, 2026 4 Mar 2, 2026 4 Mar 2, 2026 S-8 Feb 27, 2026 424B4 Feb 27, 2026 EFFECT Feb 26, 2026 3 Feb 26, 2026 3 Feb 26, 2026 3 Feb 26, 2026 3 Feb 26, 2026 3 Feb 26, 2026 3 Feb 26, 2026 3 Feb 26, 2026 3 Feb 26, 2026 3 Feb 26, 2026 3 Feb 26, 2026 3 Feb 26, 2026 3 Feb 26, 2026 3 Feb 26, 2026 3 Feb 26, 2026 3 Feb 26, 2026